Clinical evidence and rationale of mesoglycan to treat chronic venous disease and hemorrhoidal disease: a narrative review - Takeaways - MDSpire

Clinical evidence and rationale of mesoglycan to treat chronic venous disease and hemorrhoidal disease: a narrative review

  • By

  • Gaetano Gallo

  • Arcangelo Picciariello

  • Antonella Tufano

  • Giuseppe Camporese

  • February 14, 2024

  • 0 min

Share

  • 1

    Chronic venous disease (CVD) and hemorrhoidal disease (HD) are prevalent vascular conditions affecting significant portions of the population.

  • 2

    CVD symptoms include leg pain, swelling, and skin changes, leading to a decline in health-related quality of life.

  • 3

    Mesoglycan, derived from porcine intestinal mucosa, is a glycosaminoglycan preparation used to treat CVD and HD.

  • 4

    The review aims to evaluate mesoglycan's clinical effects and its mechanism of action in modifying pathophysiological processes.

  • 5

    Endothelial dysfunction and inflammation in CVD contribute to structural vein changes, exacerbating symptoms and complications.

Original Source(s)

Clinical evidence and rationale of mesoglycan to treat chronic venous disease and hemorrhoidal disease: a narrative review

  • by Gaetano Gallo, Arcangelo Picciariello, Antonella Tufano, Giuseppe Camporese

  • February 14, 2024

Related Content

Extending bioelectric navigation for displacement and direction detection

Current Concepts in Vascular Therapies

Save the date! The 14th annual Current Concepts in Vascular Therapies will be held on April 16-18, 2026.

  • by

  • October 3, 2025

  • 2 min
Image-based hemodynamic simulations for intracranial aneurysms: the impact of complex vasculature